Processa Pharmaceuticals (PCSA) R&D head adds 1,810 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals Pres. of Research & Development David Young bought 1,810 shares of common stock in an open-market purchase at $2.535 per share. After this trade, he directly holds 10,562 shares and has additional indirect holdings through the Young-Plaisance Revocable Trust, family entities, and CorLyst, LLC.

Insider Trade Summary

Net Buyer: 1,810 shares ($4,588)

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 1,810 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,810	$2.535	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 10,562 shares (Direct); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust)

Footnotes (1)

Key Figures

Open-market purchase: 1,810 shares Purchase price: $2.535 per share Direct holdings after trade: 10,562 shares +3 more

6 metrics

Open-market purchase 1,810 shares Common Stock bought in open market

Purchase price $2.535 per share Price for 1,810 Common Stock shares

Direct holdings after trade 10,562 shares Common Stock held directly post-transaction

Indirect holdings via Young-Plaisance Revocable Trust 1,242 shares Common Stock held indirectly

Indirect holdings via family entities 432 shares Common Stock held indirectly

Indirect holdings via CorLyst, LLC 742 shares Common Stock held indirectly

Key Terms

open-market purchase, indirect ownership, revocable trust, Family Entities, +1 more

5 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

""direct_or_indirect": "I","nature_of_ownership""

revocable trust financial

""nature_of_ownership": "By Young-Plaisance Revocable Trust""

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Family Entities financial

""nature_of_ownership": "By Family Entities""

CorLyst, LLC financial

""nature_of_ownership": "By CorLyst, LLC""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		1,810	A	$2.535	10,562	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								742	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive David Young report?

David Young reported an open-market purchase of 1,810 Processa Pharmaceuticals common shares. He paid $2.535 per share, increasing his direct ownership to 10,562 shares while also reporting separate indirect holdings through trusts, family entities, and CorLyst, LLC.

At what price did David Young buy Processa Pharmaceuticals (PCSA) shares?

David Young purchased 1,810 Processa Pharmaceuticals common shares at $2.535 per share. This price reflects an open-market transaction and is the only reported purchase price in this filing, which also details his direct and indirect post-transaction share positions.

How many Processa Pharmaceuticals (PCSA) shares does David Young now hold directly?

Following the reported trade, David Young directly holds 10,562 Processa Pharmaceuticals common shares. The Form 4 also lists additional indirect holdings in separate lines, which are held through a revocable trust, family-related entities, and CorLyst, LLC.

What indirect PCSA holdings are associated with David Young in this Form 4?

The filing shows indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC. These entries reflect ownership through related entities rather than additional open-market purchases.

Was David Young’s PCSA Form 4 transaction a buy or a sell?

The Form 4 reports a buy transaction. David Young completed an open-market purchase of 1,810 Processa Pharmaceuticals common shares, coded as a “P” transaction, with no reported sales or derivative exercises in this filing.

Does this PCSA Form 4 include any derivative securities or option exercises?

This Form 4 does not report any derivative securities or option exercises. The derivative section is empty, and the only reported transaction is an open-market purchase of common stock, plus separate lines showing post-transaction indirect common share holdings.